Envista Holdings
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 21 in the most recent period (2026/Q3).
- Total institutional ownership rose 8.7 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 127.68% +8.75pp
- Institutions
- 474 +21
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Paul Keel | Chairperson & CEO | 0.13% |
| Amir Aghdaei | Former Chief Executive Officer | 0.09% |
| Barbara Hulit | Former Independent Director | 0.04% |
| Mark Nance | Senior Vice President | 0.04% |
| Eric Hammes | Senior Vice President | 0.03% |
| Stefan Nilsson | President of Nobel Biocare | 0.02% |
| Faez Kaabi | Former VP, Chief Accounting Officer & Corporate Controller | 0.02% |
| Robert Befidi | Senior VP & President of Diagnostics | 0.02% |
| Mischa Reis | Senior Vice President of Strategy & Corporate Development | 0.02% |
| Veronica Acurio | Senior VP & President of Orthodontics | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-31 | Paul Keel | Chairperson & CEO | Sale to Issuer | -54,197 | $23.51 |
| 2026-08-24 | Robert Befidi | Senior VP & President of Diagnostics | Sale to Issuer | -5,147 | $27.47 |
| 2026-08-24 | Eric Hammes | Senior Vice President | Sale to Issuer | -10,885 | $27.47 |
| 2026-08-24 | Veronica Acurio | Senior VP & President of Orthodontics | Sale to Issuer | -7,710 | $27.47 |
| 2026-08-24 | Stefan Nilsson | President of Nobel Biocare | Sale to Issuer | -804 | $27.47 |
| 2026-08-19 | Mischa Reis | Senior Vice President of Strategy & Corporate Development | Automatic Disposition | -8,000 | $27.50 |
| 2026-08-17 | Paul Keel | Chairperson & CEO | Other Acquisition | +179,730 | -- |
| 2026-08-17 | Paul Keel | Chairperson & CEO | Other Derivative Acquisition | +159,900 | -- |
| 2026-08-17 | Eric Hammes | Senior Vice President | Other Derivative Acquisition | +47,970 | -- |
| 2026-08-05 | Coree Thomas | Vice President | Initial Statement of Beneficial | 0 | -- |
| 2026-05-24 | Paul Keel | Chairperson & CEO | Sale to Issuer | -12,811 | $23.43 |
| 2026-05-18 | Daniel Raskas | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Christine Tsingos | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Kieran Gallahue | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Richard Huennekens | Lead Independent Director | Other Acquisition | +12,585 | -- |
| 2026-05-18 | Vivek Jain | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Wendy Carruthers | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | J. Pierce | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-02-24 | Paul Keel | Chairperson & CEO | Sale to Issuer | -11,840 | $29.59 |
| 2026-02-24 | Paul Keel | Chairperson & CEO | Other Acquisition | +48,670 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:33 · For reference only, not investment advice and not tailored to your situation.
Envista Holdings discussion 0 comments